1. Home
  2. LQDA vs NATL Comparison

LQDA vs NATL Comparison

Compare LQDA & NATL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

LQDA

Liquidia Corporation

HOLD

Current Price

$37.68

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Logo NCR Atleos Corporation

NATL

NCR Atleos Corporation

HOLD

Current Price

$39.99

Market Cap

2.9B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
LQDA
NATL
Founded
2004
2023
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
2.9B
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
LQDA
NATL
Price
$37.68
$39.99
Analyst Decision
Strong Buy
Buy
Analyst Count
10
4
Target Price
$38.60
$42.75
AVG Volume (30 Days)
1.9M
353.9K
Earning Date
11-03-2025
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
1.74
Revenue
$69,216,000.00
$4,322,000,000.00
Revenue This Year
$1,005.03
$2.83
Revenue Next Year
$204.13
$3.96
P/E Ratio
N/A
$22.94
Revenue Growth
343.41
0.63
52 Week Low
$11.26
$22.30
52 Week High
$41.57
$42.23

Technical Indicators

Market Signals
Indicator
LQDA
NATL
Relative Strength Index (RSI) 60.22 58.04
Support Level $29.41 $39.08
Resistance Level $41.57 $41.01
Average True Range (ATR) 3.03 1.09
MACD 0.43 0.10
Stochastic Oscillator 68.38 75.87

Price Performance

Historical Comparison
LQDA
NATL

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About NATL NCR Atleos Corporation

NCR Atleos Corp is financial technology company providing self-directed banking solutions to a customer base including financial institutions, merchants, manufacturers, retailers and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware and its proprietary Allpoint network. Atleos manage its operations in the following segments which includes Self-Service Banking, Network, and Telecommunications abd Technology.

Share on Social Networks: